Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Roche Pharma AG | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| bevacizumab combined neoadjuvant chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bevacizumab | Drug | The patients will be treated with Avastin combined neoadjuvant chemotherapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | From enrollment to disease progression |
| Measure | Description | Time Frame |
|---|---|---|
| overall response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | From enrollment to disease progression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Breast cancer patients of vascular endocrine surgery department in Xijing Hospital
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nanlin Li, Phd | Contact | +86-186-2963-7041 | nanlin-74@163.com | |
| Hongyu Xiao, Master | Contact | +86-186-2963-7040 | louch2008@116.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xijing Hospital ， Fourth Military Medical University | Recruiting | Xi'an | Shaanxi | 710032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided